Mouse anti Human HLA-DR conjugated with FITC
| Code | Size | Price |
|---|
| EXA-0DR2 | 100 Tests | £221.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2a
Antibody Clonality: Monoclonal
Antibody Clone: 423L
Regulatory Status: RUO
Application: Flow Cytometry
Shipping:
room temperature
Storage:
Product should be stored at 4-8°C. DO NOT FREEZE
Further Information
Applications Description:
PBMC: Add 10 ?l of MAB/10^6 PBMC in 100 ?l PBS. Mix gently and incubate for 15 minutes at 2? to 8?C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze.
WHOLE BLOOD: Add10 ?l of MAB/100 ?l of whole blood. Mix gently and incubate for 15 minutes at room temperature 20?C. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer?s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
WHOLE BLOOD: Add10 ?l of MAB/100 ?l of whole blood. Mix gently and incubate for 15 minutes at room temperature 20?C. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer?s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Background:
HLA-DR is used for the identification of human B cell and T cell subsets associated with approximately 10% of peripheral blood lymphocytes 28-34,000 M.W. surface antigen, and is present in low density on monocytes and macrophages.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
Titered for flow cytometry
Field of Interest:
Flow Cytometry
Formulation:
Provided as sterile filtered solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Functional Analysis:
Flow Cytometry Staining
Immunogen:
HLA-DR=Derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human lymphoblastoid B-cell line RPMI 8866
Label:
FITC
Product:
Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Product Form:
FITC
Product Stability:
Reagents are stable for the period shown on the vial label when stored properly
Purification Method:
Protein A/G Chromatography
Source:
Derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human lymphoblastoid B-cell line RPMI 8866
Synonyms:
HLA-DR* FITC
UniProt:
P04233
References
1. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. Gerrard T.L., Dyer D.R., Mostowski H.S., J. Immunol. 1990 June, 1;144(12): 4670-4.
2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp.. Med. 1990 March ;171(3):615-28.
3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4.
4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2.
5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704.
6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.
2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp.. Med. 1990 March ;171(3):615-28.
3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4.
4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2.
5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704.
6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.